Aktis Oncology Inc(AKTS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | - | Insider Own | 43.37% | Shs Outstand | 53.5M | Perf Week | -14.34% |
| Market Cap | 1.29B | Forward P/E | - | EPS next Y | -26.32% | Insider Trans | -0.45% | Shs Float | 31.5M | Perf Month | -2.61% |
| Enterprise Value | 0.78B | PEG | - | EPS next Q | -0.46 | Inst Own | 43.54% | Short Float | 10.08% | Perf Quarter | 5.65% |
| Income | - | P/S | - | EPS this Y | 97.72% | Inst Trans | -0.83% | Short Ratio | 7.89 | Perf Half Y | 22.01% |
| Sales | - | P/B | 2.64 | EPS next 5Y | 68.43% | ROA | - | Short Interest | 3.18M | Perf YTD | -14.19% |
| Book/sh | 8.76 | P/C | 2.49 | EPS past 3/5Y | -47.94% - | ROE | - | 52W High | -32.23% ($34.19) | Perf Year | - |
| Cash/sh | 9.3 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 57.4% ($14.72) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 6.5% 5.68% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.42 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 16.33 | EPS Q/Q | -55.52% | Profit Margin | - | RSI (14) | 38.72 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 16.33 | Sales Q/Q | 133.86% | SMA20 | -8.41% ($25.3) | Beta | - | Target Price | $35.41 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/8/13 | SMA50 | -6.92% ($24.89) | Rel Volume | 0.82 | Prev Close | $23.3 |
| Employees | 79 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | -0.19% 25.44% | SMA200 | 7.39% ($21.58) | Avg Volume(3M) | 0.40M | Price | $23.17 |
| IPO | 2026/1/9 | Option/Short | Yes/Yes | Trades | 6560 | Volume | 330,076 | Change | -0.56% |
Company
AKTS is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Actis Oncology (AKTS) is a clinical-stage oncology biotech developing targeted radiopharmaceuticals that deliver alpha-emitting isotopes directly to tumors. Through its proprietary miniprotein radio-conjugate platform, it pursues strong tumor binding and penetration along with rapid clearance from healthy tissue, with the goal of improving the therapeutic index. It is classified as a next-generation alpha radiopharmaceutical company aiming to expand its reach into solid tumor patient populations.
Over the past 1 year, roughly in the middle
32% below its 1-year high.
AKTS makes money exceptionally well
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +97.7% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are close to the market
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 43.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
TMED 0.00%
IWO 0.00%
RESM 0.00%
IWM 0.00%
ITWO 0.00%It ranks #4 in the industry
Based on market cap of $1B.
AKTS $1B PER -
VRTX $132B PER 30.2
REGN $82B PER 19.6
ARGX $62B PER 37.8
FAQ
What kind of company is AKTS?
AKTS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AKTS?
The market cap of AKTS is approximately $1.3B, ranking 2,441 within its sector.
What is the 52-week high and low for AKTS?
AKTS has recorded a 52-week high of $34.19 and a low of $14.72.
